Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Glioblastoma | Research

TERT mutations-associated alterations in clinical characteristics, immune environment and therapy response in glioblastomas

Authors: Feng Tang, Xi Chen, Jin-Sheng Liu, Zhen-Yuan Liu, Jin-Zhou Yang, Ze-Fen Wang, Zhi-Qiang Li

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Objective TERT

is the most frequently mutated gene in adult glioblastomas (GBMs) defined by the 2021 World Health Organization classification system. The present study aims to explore differences in clinical characteristics and immune microenvironment between TERT mutant and wild-type GBM.

Methods

Three GBM-related cohorts consisting of 205 GBM patients in our cohort, 463 GBM patients without immune checkpoint inhibitor(ICI) therapy and 1465 tumour patients (including 92 GBM cases) receiving ICI treatment in the MSK cohort were included. Retrospective analysis and immunohistochemistry assay were used for investigating the local (including tumour cells, local immune cells, and seizures) and systemic (including circulating immune cells, coagulation-related functions, and prognosis) effects of TERT mutations. Besides, differences in genetic alterations and immunotherapy responses between TERT mutant and wild-type GBMs were also explored.

Results

We found that TERT mutant and wild-type GBMs possessed similar initial clinic symptoms, circulating immune microenvironment and immunotherapy response. With respect to that in TERT wild-type GBMs, mutations in TERT resulted in higher levels of tumour-infiltrating neutrophils, prolonged coagulation time, worse chemotherapy response and poorer overall survival.

Conclusion

Mutations in TERT alter the local immune environment and decrease the sensitivity of GBM to chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, Bhute V, Torregrosa-Allen S, Elzey B, Won Y, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14(1):2266.CrossRefPubMedPubMedCentral
2.
Jiang T, Wan J, Qiu X, Mao Y, Ma W. Chinese guidelines for the diagnosis and treatment of Glioma. Natl Health Comm People’s Repub China. 2022;34(5):425.
3.
Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W, Ohgaki H, Wiestler O, Kleihues P, Ellison D. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.CrossRefPubMed
4.
Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D, Hawkins C, Ng H, Pfister S, Reifenberger G, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neurooncology. 2021;23(8):1231–51.
5.
Lee J, Hong J, Zhang Z, de la Peña AB, Proietti C, Deamicis A, Guzmán GP, Lam H, Garcia J, Roudier M, et al. NRegulation of telomere homeostasis and genomic stability in cancer by -adenosine methylation (mA). Sci Adv. 2021;7(31):7073.CrossRef
6.
7.
Heidenreich B, Kumar R. TERT promoter mutations in telomere biology. Mutat Res Reviews Mutat Res. 2017;771:15–31.CrossRef
8.
Dey A, Chakrabarti K. Current perspectives of Telomerase structure and function in eukaryotes with emerging views on telomerase in human parasites. Int J Mol Sci. 2018;19(2):333.CrossRefPubMedPubMedCentral
9.
10.
Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172–83.CrossRefPubMedPubMedCentral
11.
Ohba S, Kuwahara K, Yamada S, Abe M, Hirose Y. Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Brain Tumor Pathol. 2020;37(2):33–40.CrossRefPubMed
12.
Mao J, Zhang Q, Wang Y, Zhuang Y, Xu L, Ma X, Guan D, Zhou J, Liu J, Wu X, et al. TERT activates endogenous retroviruses to promote an immunosuppressive tumour microenvironment. EMBO Rep. 2022;23(4):e52984.CrossRefPubMedPubMedCentral
13.
14.
Eckel-Passow J, Lachance D, Molinaro A, Walsh K, Decker P, Sicotte H, Pekmezci M, Rice T, Kosel M, Smirnov I, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508.CrossRefPubMedPubMedCentral
15.
Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.CrossRefPubMedPubMedCentral
16.
Tang F, Pan Z, Wang Y, Lan T, Wang M, Li F, Quan W, Liu Z, Wang Z, Li Z. Advances in the immunotherapeutic potential of Isocitrate dehydrogenase mutations in Glioma. Neurosci Bull. 2022;38(9):1069–84.CrossRefPubMedPubMedCentral
17.
Varn F, Johnson K, Martinek J, Huse J, Nasrallah M, Wesseling P, Cooper L, Malta T, Wade T, Sabedot T, et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 2022;185(12):2184–2199e2116.CrossRefPubMedPubMedCentral
18.
19.
Duan W, Wang L, Li K, Wang W, Zhan Y, Zhang F, Yu B, Bai Y, Wang Y, Ji Y, et al. IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas. Medicine. 2018;97(50):e13675.CrossRefPubMedPubMedCentral
20.
Fridlender Z, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen G, Albelda S. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–94.CrossRefPubMedPubMedCentral
21.
Egholm C, Heeb L, Impellizzieri D, Boyman O. The regulatory effects of interleukin-4 receptor signaling on neutrophils in type 2 Immune responses. Front Immunol. 2019;10:2507.CrossRefPubMedPubMedCentral
22.
Quillien V, Carpentier A, Gey A, Avril T, Tartour E, Sejalon F, Campillo-Gimenez B, Vauleon E. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients. Cancer Immunol, Immunother. 2019;68(6):871–82.CrossRefPubMed
23.
Liu D, Ye Z, Chen S, Sun X, Hou J, Zhao Z, Long H. Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients. J cancer Res Clin Oncol. 2020;146(3):801–7.CrossRefPubMed
24.
25.
Zha C, Meng X, Li L, Mi S, Qian D, Li Z, Wu P, Hu S, Zhao S, Cai J, et al. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment the HMGB1/RAGE/IL-8 axis. Cancer biology medicine. 2020;17(1):154–68.CrossRefPubMedPubMedCentral
26.
Khan S, Mittal S, McGee K, Alfaro-Munoz K, Majd N, Balasubramaniyan V, de Groot J. Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance. Int J Mol Sci. 2020;21(6):1954.CrossRefPubMedPubMedCentral
27.
Li J, Li Z, Zhang C, Zhang C, Wang H. Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma. Aging. 2020;12(17):17288–94.CrossRefPubMedPubMedCentral
28.
Zhao L, Luo T, Jiang J, Wu J, Zhang X. Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma. Front Mol Biosci. 2022;9:1001792.CrossRefPubMedPubMedCentral
Metadata
Title
TERT mutations-associated alterations in clinical characteristics, immune environment and therapy response in glioblastomas
Authors
Feng Tang
Xi Chen
Jin-Sheng Liu
Zhen-Yuan Liu
Jin-Zhou Yang
Ze-Fen Wang
Zhi-Qiang Li
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00760-w

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

Clinical features and prognosis of double primary malignant neoplasms in patients with non-hodgkin lymphoma

Research

MUC13 promotes the development of esophageal cancer by upregulating the expression of o-glycan process-related molecules

Research

A risk score model based on lipid metabolism-related genes could predict response to immunotherapy and prognosis of lung adenocarcinoma: a multi-dataset study and cytological validation

Research

A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer

Research

Effects of metalloprotease ADAMTS12 on cervical cancer cell phenotype and its potential mechanism

Research

CT-measured body composition radiomics predict lymph node metastasis in localized pancreatic ductal adenocarcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits